Lower-Risk MDS

Management - multipenia/neutropenia

• HMA
  • may be able to use 3d cycles, rather than 5/7
  • 29% CR or PR (12% w best supportive care)
  • oral azacitidine
    • CC-486, "Onureg"
    • RBC-TI 31% (placebo 11%)¹
    • this study used IPSS: ~30% would have been upstaged w IPSS-R
• ATG